Incretin-Based Drugs, Congestive Heart Failure: Are They Linked?
the MPR take:
Is there an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes taking incretin-based drugs? A study in the journal Diabetes Care tracked 57,737 patients who were newly prescribed diabetic medications with no prior history of CHF for an average of 2.4 years. Current use of incretin-based drug were not associated with an increased risk of CHF (adjusted OR 0.85 [95% CI 0.62–1.16]), with secondary analyses showing no duration-response relationship (P= 0.39). Although these findings need to be replicated in additional large-scale studies, there presently appears to be no increased risk of CHF for patients with type 2 diabetes on incretin-based therapy.
OBJECTIVE: To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes.
READ FULL ARTICLE From Diabetesjournals